Bioneer Corporation Logo

Bioneer Corporation

064550.KQ

(0.0)
Stock Price

20.050,00 KRW

-4.13% ROA

-5.96% ROE

-50.65x PER

Market Cap.

681.391.920.000,00 KRW

24.67% DER

0% Yield

-4.55% NPM

Bioneer Corporation Stock Analysis

Bioneer Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bioneer Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Bioneer Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bioneer Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Hold

Bioneer Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bioneer Corporation Revenue
Year Revenue Growth
2012 20.533.917.880
2013 23.904.100.690 14.1%
2014 17.853.516.180 -33.89%
2015 20.833.715.307 14.3%
2016 21.703.614.699 4.01%
2017 23.267.735.474 6.72%
2018 24.077.825.956 3.36%
2019 36.292.396.635 33.66%
2020 206.987.464.643 82.47%
2021 223.743.694.062 7.49%
2022 218.394.453.243 -2.45%
2023 294.964.363.360 25.96%
2023 263.236.802.635 -12.05%
2024 313.776.000.000 16.11%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bioneer Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2012 5.330.631.000
2013 5.746.809.000 7.24%
2014 5.879.613.000 2.26%
2015 6.013.633.000 2.23%
2016 6.887.897.000 12.69%
2017 8.070.583.000 14.65%
2018 10.420.245.000 22.55%
2019 12.097.745.000 13.87%
2020 13.118.120.000 7.78%
2021 20.001.716.000 34.42%
2022 16.751.106.000 -19.41%
2023 17.417.140.000 3.82%
2023 21.110.335.000 17.49%
2024 24.611.500.000 14.23%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bioneer Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 150.530.000
2013 173.653.000 13.32%
2014 99.895.000 -73.84%
2015 129.133.000 22.64%
2016 166.448.000 22.42%
2017 125.210.000 -32.94%
2018 97.582.000 -28.31%
2019 183.218.000 46.74%
2020 1.455.757.000 87.41%
2021 24.121.376.000 93.96%
2022 4.130.513.000 -483.98%
2023 158.496.000 -2506.07%
2023 5.642.439.000 97.19%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bioneer Corporation EBITDA
Year EBITDA Growth
2012 -90.936.300
2013 587.675.010 115.47%
2014 -5.328.901.980 111.03%
2015 -417.742.980 -1175.64%
2016 -7.636.941.440 94.53%
2017 -2.264.286.180 -237.28%
2018 -8.091.276.460 72.02%
2019 -5.831.255.040 -38.76%
2020 109.356.423.480 105.33%
2021 50.073.149.520 -118.39%
2022 18.003.515.690 -178.13%
2023 25.147.449.240 28.41%
2023 2.923.718.830 -760.12%
2024 -2.380.000.000 222.85%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bioneer Corporation Gross Profit
Year Gross Profit Growth
2012 11.246.057.400
2013 14.335.001.700 21.55%
2014 10.196.605.360 -40.59%
2015 10.392.667.084 1.89%
2016 8.079.341.050 -28.63%
2017 10.807.312.592 25.24%
2018 10.661.662.186 -1.37%
2019 15.299.317.655 30.31%
2020 159.686.245.547 90.42%
2021 172.156.193.634 7.24%
2022 163.415.037.654 -5.35%
2023 236.504.410.080 30.9%
2023 199.253.109.649 -18.7%
2024 231.182.527.784 13.81%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bioneer Corporation Net Profit
Year Net Profit Growth
2012 -8.022.353.080
2013 -7.152.484.830 -12.16%
2014 -13.559.179.820 47.25%
2015 -5.372.140.420 -152.4%
2016 -14.418.909.089 62.74%
2017 -9.941.285.943 -45.04%
2018 -8.818.353.336 -12.73%
2019 -7.826.653.510 -12.67%
2020 57.899.192.630 113.52%
2021 27.159.523.570 -113.18%
2022 12.076.878.840 -124.89%
2023 1.903.790.280 -534.36%
2023 -10.587.029.811 117.98%
2024 -7.428.000.000 -42.53%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bioneer Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -640
2013 -565 -13.27%
2014 -992 43.04%
2015 -348 -185.88%
2016 -863 59.79%
2017 -539 -60.11%
2018 -428 -26.23%
2019 -361 -18.61%
2020 2.509 114.35%
2021 1.073 -133.74%
2022 468 -129.76%
2023 72 -548.61%
2023 -410 117.56%
2024 -288 -42.86%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bioneer Corporation Free Cashflow
Year Free Cashflow Growth
2012 -3.499.374.370
2013 -4.339.157.910 19.35%
2014 -4.656.767.940 6.82%
2015 -3.953.961.133 -17.77%
2016 -8.900.580.137 55.58%
2017 -7.323.853.352 -21.53%
2018 -12.359.322.034 40.74%
2019 -10.351.569.949 -19.4%
2020 41.399.863.469 125%
2021 9.888.852.243 -318.65%
2022 -9.718.391.345 201.75%
2023 -1.355.634.908 -616.89%
2023 4.830.270.720 128.07%
2024 5.874.324.879 17.77%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bioneer Corporation Operating Cashflow
Year Operating Cashflow Growth
2012 -2.714.095.840
2013 -3.787.214.090 28.34%
2014 -4.314.334.030 12.22%
2015 407.678.862 1158.27%
2016 -2.511.535.212 116.23%
2017 -3.902.011.230 35.63%
2018 -8.113.572.202 51.91%
2019 -5.589.453.062 -45.16%
2020 95.705.376.696 105.84%
2021 53.174.659.310 -79.98%
2022 8.805.263.177 -503.9%
2023 4.135.856.106 -112.9%
2023 5.753.935.620 28.12%
2024 7.498.928.853 23.27%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bioneer Corporation Capital Expenditure
Year Capital Expenditure Growth
2012 785.278.530
2013 551.943.820 -42.28%
2014 342.433.910 -61.18%
2015 4.361.639.995 92.15%
2016 6.389.044.925 31.73%
2017 3.421.842.122 -86.71%
2018 4.245.749.832 19.41%
2019 4.762.116.887 10.84%
2020 54.305.513.227 91.23%
2021 43.285.807.067 -25.46%
2022 18.523.654.522 -133.68%
2023 5.491.491.014 -237.32%
2023 923.664.900 -494.53%
2024 1.624.603.974 43.15%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bioneer Corporation Equity
Year Equity Growth
2012 31.423.237.130
2013 29.536.970.410 -6.39%
2014 30.201.874.080 2.2%
2015 34.531.437.915 12.54%
2016 26.114.903.493 -32.23%
2017 27.145.814.064 3.8%
2018 39.036.924.835 30.46%
2019 31.619.155.141 -23.46%
2020 147.959.761.505 78.63%
2021 207.591.626.721 28.73%
2022 243.539.618.432 14.76%
2023 249.467.869.520 2.38%
2023 234.876.815.089 -6.21%
2024 232.605.074.222 -0.98%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bioneer Corporation Assets
Year Assets Growth
2012 68.131.984.580
2013 69.934.206.880 2.58%
2014 67.359.505.869 -3.82%
2015 71.985.447.610 6.43%
2016 81.801.741.226 12%
2017 58.695.411.475 -39.37%
2018 70.807.117.625 17.11%
2019 82.099.865.831 13.75%
2020 191.165.848.661 57.05%
2021 262.418.107.707 27.15%
2022 298.737.345.184 12.16%
2023 320.119.089.690 6.68%
2023 315.487.269.002 -1.47%
2024 326.040.342.963 3.24%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bioneer Corporation Liabilities
Year Liabilities Growth
2012 36.708.747.460
2013 40.397.236.460 9.13%
2014 37.157.631.780 -8.72%
2015 37.454.009.695 0.79%
2016 55.686.837.733 32.74%
2017 31.549.597.411 -76.51%
2018 31.770.192.790 0.69%
2019 50.480.710.690 37.06%
2020 43.206.087.156 -16.84%
2021 54.826.480.986 21.19%
2022 55.197.726.752 0.67%
2023 70.651.220.170 21.87%
2023 80.610.453.913 12.35%
2024 93.435.268.741 13.73%

Bioneer Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
11449.61
Net Income per Share
-521.26
Price to Earning Ratio
-50.65x
Price To Sales Ratio
2.31x
POCF Ratio
131.58
PFCF Ratio
2339.15
Price to Book Ratio
3.11
EV to Sales
2.28
EV Over EBITDA
-788.86
EV to Operating CashFlow
130.17
EV to FreeCashFlow
2314.1
Earnings Yield
-0.02
FreeCashFlow Yield
0
Market Cap
681,39 Bil.
Enterprise Value
674,10 Bil.
Graham Number
9977.03
Graham NetNet
1615.15

Income Statement Metrics

Net Income per Share
-521.26
Income Quality
-0.32
ROE
-0.06
Return On Assets
-0.04
Return On Capital Employed
-0.02
Net Income per EBT
4.49
EBT Per Ebit
0.61
Ebit per Revenue
-0.02
Effective Tax Rate
-2.85

Margins

Sales, General, & Administrative to Revenue
0.21
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.75
Operating Profit Margin
-0.02
Pretax Profit Margin
-0.01
Net Profit Margin
-0.05

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
200.64
Free CashFlow per Share
11.29
Capex to Operating CashFlow
0.94
Capex to Revenue
0.02
Capex to Depreciation
0.57
Return on Invested Capital
-0.07
Return on Tangible Assets
-0.04
Days Sales Outstanding
15.32
Days Payables Outstanding
21.73
Days of Inventory on Hand
194.99
Receivables Turnover
23.82
Payables Turnover
16.79
Inventory Turnover
1.87
Capex per Share
189.35

Balance Sheet

Cash per Share
4.116,11
Book Value per Share
9.012,11
Tangible Book Value per Share
9012.11
Shareholders Equity per Share
8487.27
Interest Debt per Share
2136.62
Debt to Equity
0.25
Debt to Assets
0.17
Net Debt to EBITDA
8.54
Current Ratio
2.32
Tangible Asset Value
232,61 Bil.
Net Current Asset Value
67,06 Bil.
Invested Capital
241174703675
Working Capital
91,40 Bil.
Intangibles to Total Assets
0
Average Receivables
13,15 Bil.
Average Payables
4,55 Bil.
Average Inventory
42122418489.5
Debt to Market Cap
0.08

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bioneer Corporation Dividends
Year Dividends Growth
2022 0

Bioneer Corporation Profile

About Bioneer Corporation

Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analysis, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, electrophoresis, spectrophotometer, and microbial culture. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal diseases and nano-bio products. The company was founded in 1992 and is headquartered in Daejeon, South Korea.

CEO
Han-Oh Park
Employee
608
Address
8-11, Munpyeongseo-ro
Daejeon,

Bioneer Corporation Executives & BODs

Bioneer Corporation Executives & BODs
# Name Age
1 Han-Oh Park
Founder, Chief Executive Officer & Chairman
70
2 Jae-Hyung Yu
Head of Sales Division and Director
70
3 Young-Cheol Choi
Executive Officer
70
4 Mr. Sang-Chul Kim
Executive Officer
70
5 Geun-Bok Seo
Executive Officer
70
6 Pil-Ho Lee
Executive Officer
70
7 Mr. Jae-Ha Kim
Director and Director of Nano Bio Bus. Division
70
8 Seung-Wook Ham
Executive Officer
70
9 Jin-Pyeong Jeong
Director and Head of Management Support Division
70
10 Mr. Tai-Hyung Park
Executive Officer
70

Bioneer Corporation Competitors

Seegene, Inc. Logo
Seegene, Inc.

096530.KQ

(0.0)
Medy-Tox Inc. Logo
Medy-Tox Inc.

086900.KQ

(0.0)
ALTEOGEN Inc. Logo
ALTEOGEN Inc.

196170.KQ

(0.0)
Green Cross Corporation Logo
Green Cross Corporation

006280.KS

(2.0)
Pharmicell Co., Ltd. Logo
Pharmicell Co., Ltd.

005690.KS

(1.8)